You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
GBR 12935 dihydrochloride
Biological Activity for GBR 12935 dihydrochloride
GBR 12935 dihydrochloride is a potent and selective inhibitor of dopamine uptake (KD = 5.5 nM in rat striatal membranes).
Technical Data for GBR 12935 dihydrochloride
|Storage||Desiccate at -20°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Solubility Data for GBR 12935 dihydrochloride
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions for GBR 12935 dihydrochloride
The following data is based on the product molecular weight 487.51. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|0.05 mM||41.02 mL||205.12 mL||410.25 mL|
|0.25 mM||8.2 mL||41.02 mL||82.05 mL|
|0.5 mM||4.1 mL||20.51 mL||41.02 mL|
|2.5 mM||0.82 mL||4.1 mL||8.2 mL|
Product Datasheets for GBR 12935 dihydrochloride
References for GBR 12935 dihydrochloride
References are publications that support the biological activity of the product.
Andersen et al (1987) Biochemical and pharmacological characterization of [3H]GBR 12935 binding in vitro to rat striatal membranes: labelling of the DA uptake complex. J.Neurochem. 48 1887 PMID: 2952763
Reith et al (1994) GBR 12909 and 12935 block DA uptake into brain synaptic vesicles as well as nerve endings. Eur.J.Pharmacol. 253 175 PMID: 8013544
Reith et al (1992) Evidence for mutually exclusive binding of cocaine, BTCP, GBR 12935, and DA to the DA transporter. Eur.J.Pharmacol. 227 417 PMID: 1446712
If you know of a relevant reference for GBR 12935 dihydrochloride, please let us know.
View Related Products by Product Action
Keywords: GBR 12935 dihydrochloride, GBR 12935 dihydrochloride supplier, Selective, dopamine, uptake, inhibitors, inhibits, DAT, Transporters, Monoamine, Neurotransmitter, GBR12935, dihydrochloride, Dopamine, 0514, Tocris Bioscience
Citations for GBR 12935 dihydrochloride
Citations are publications that use Tocris products.
Currently there are no citations for GBR 12935 dihydrochloride. Do you know of a great paper that uses GBR 12935 dihydrochloride from Tocris? Please let us know.
Reviews for GBR 12935 dihydrochloride
There are currently no reviews for this product. Be the first to review GBR 12935 dihydrochloride and earn rewards!
Have you used GBR 12935 dihydrochloride?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Dopamine Receptors Scientific Review
Written by Phillip Strange and revised by Kim Neve in 2013, this review summarizes the history of the dopamine receptors and provides an overview of individual receptor subtype properties, their distribution and identifies ligands which act at each receptor subtype. Compounds available from Tocris are listed.
The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.